Competition Regulation and Recombinant Drugs in India

Ravikant Bhardwaj
Padmavati Manchikanti
Associate Professor and Acting Dean Rajiv Gandhi School of IP Law IIT Kharagpur Kharagpur
K.D. Raju

DOI:https://doi.org/10.5912/jcb609

Abstract:

The recombinant drug industry is growing at almost 20% rate in India. The long term growth of this sector depends upon the innovation as well as competition and market. The structure, conduct and performance of firms in market plays a very important role in predicting the future of innovation and competition in market. The present paper analyses the structure-conduct-performance paradigm in the context of recombinant drug sector in India. The analysis reveals that R&D, distribution chains and advertisement has significant effect on the profits of firms in the recombinant drug sector.

Keywords:competition ,recombinant drugs ,SCP model ,en ,